Molecular Characterization of AZD7442 (Tixagevimab-Cilgavimab) Neutralization of SARS-CoV-2 Omicron Subvariants

Therapeutic anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibodies (MAbs) provide immunosuppressed and vulnerable populations with prophylactic and treatment interventions against coronavirus disease 2019 (COVID-19). AZD7442 (tixagevimab-cilgavimab) is a combination...

Descripción completa

Detalles Bibliográficos
Autores principales: Roe, Tiffany L., Brady, Tyler, Schuko, Nicolette, Nguyen, Amy, Beloor, Jagadish, Guest, Johnathan D., Aksyuk, Anastasia A., Tuffy, Kevin M., Zhang, Tianhui, Streicher, Katie, Kelly, Elizabeth J., Kijak, Gustavo H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10100701/
https://www.ncbi.nlm.nih.gov/pubmed/36877050
http://dx.doi.org/10.1128/spectrum.00333-23

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10100701/
https://www.ncbi.nlm.nih.gov/pubmed/36877050
http://dx.doi.org/10.1128/spectrum.00333-23

Ejemplares similares